Diagnostics

Adding a bile acid sequestrant to statin therapy reported to reduce median hs-CRP levels

Published in Drug Week, December 16th, 2005

Data presented at the American Heart Association's scientific sessions 2005 demonstrated that adding Sankyo Pharma's WelChol (colesevelam hydrochloride) to stable statin therapy (i.e., Zocor (simvastatin), Lipitor (atorvastatin calcium), or Pravachol (pravastatin sodium)) further reduced mean LDL-C, or "bad" cholesterol, and median high-sensitivity C-reactive protein (hs-CRP) levels.

This is the first data to demonstrate that WelChol, a bile acid sequestrant, when added to statin therapy, reduces hs-CRP levels, which is a marker for inflammation and also a strong predictor of coronary heart disease (CHD) events.The addition of placebo to statin therapy led to a median...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry